Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305162 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
A Phase 3 study, sponsored by The Medicines Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8,882
- Enrollment target
NCT00305162 is a Phase 3 study that was terminated before completion, run by The Medicines Company. The registered enrollment target is 8,882 participants.
The verdict
NCT00305162, a Phase 3 study, was terminated before completion, sponsored by The Medicines Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8,882 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
Interventions
- DRUG Placebo bolus & placebo infusion
- DRUG Placebo capsules - end of infusion
- DRUG Cangrelor (P2Y12 inhibitor)
- DRUG clopidogrel (oral P2Y12 inhibitor)
- DRUG Placebo capsules - as soon as possible after randomization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,882 participants |
| Start Date | 2006-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305162
The ClinicalTrials.gov registry entry for NCT00305162 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8,882 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo bolus & placebo infusion is the first listed.
NCT00305162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00305162 about?
NCT00305162 is a clinical study titled "A Clinical Trial to Demonstrate the Efficacy of Cangrelor". The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
What is the current status of trial NCT00305162?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8,882 participants. The study started on 2006-04. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00305162?
The interventions under investigation include: Placebo bolus & placebo infusion (DRUG), Placebo capsules - end of infusion (DRUG), Cangrelor (P2Y12 inhibitor) (DRUG), clopidogrel (oral P2Y12 inhibitor) (DRUG), Placebo capsules - as soon as possible after randomization (DRUG).
Who is sponsoring clinical trial NCT00305162?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.